Consultant Medicine Development Lead, ENA Respiratory

Ruth Tal-Singer

Roles

Role	Organisation	Sources
	GlaxoSmithKline	Brandon Capital portfolio (Tue 22 Jun 2021), Brandon Capital portfolio (Wed 16 Jun 2021), Brandon BioCatalyst portfolio
Board of Directors (former)	ENA Respiratory	Brandon BioCatalyst portfolio, Brandon Capital portfolio
Consultant Medicine Development Lead	ENA Respiratory	Uniseed
Medicine Development Leader (former)	ENA Respiratory	Brandon Capital, Brandon BioCatalyst, Brandon Capital portfolio (Tue 22 Jun 2021), Brandon Capital portfolio (Wed 16 Jun 2021), Brandon BioCatalyst portfolio
President and Chief Scientific Officer (former)	US COPD Foundation	Brandon Capital portfolio (Tue 22 Jun 2021), Brandon Capital portfolio (Wed 16 Jun 2021), Brandon BioCatalyst portfolio (Wed 16 Jun 2021), Brandon Capital portfolio (Tue 15 Jun 2021), Brandon BioCatalyst portfolio (Tue 15 Jun 2021)
Vice President of Medical Innovation (former)	GSK Pharmaceuticals	Brandon Capital portfolio, Brandon BioCatalyst portfolio

Coverage

Stories naming Ruth Tal-Singer. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

ENA Respiratory Begins Part B Dosing

Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.

Uniseed Tue 22 Sep 2026 Accellacare BARDA Biointelect Venturer Brandon Capital CUREator ENA Respiratory Flu Lab Johnson & Johnson Innovation Minderoo Foundation Naval Medical Research Command (NMRC) Clinical Trials Center Stoic Venture Capital Uniseed University of Maryland's Center for Vaccine Development and Global Health U.S. Government Ruth Tal-Singer

2 deals

Australian spinout eyes the clinic with a prophylactic nasal spray for Covid-19

Australian biotech ENA Respiratory raised funding led by Brandon Capital and Minderoo Foundation to advance its Covid-19 nasal spray toward the clinic, and appointed Ruth Tal-Singer to its board.

Brandon BioCatalyst portfolio Wed 16 Jun 2021 ENA Respiratory Leyden Labs ENA Therapeutics GlaxoSmithKline Google Ventures Regeneron University of Pennsylvania US COPD Foundation Brandon Capital Partners Minderoo Foundation Uniseed Dr Christophe Demaison Dr James Wilson Ruth Tal-Singer

Unnamed stage ≤$32m

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise

ENA Respiratory secured up to AU$32 million, co-led by Brandon Capital Partners and Minderoo Foundation with Uniseed, to advance its INNA-051 nasal spray, and appointed Ruth Tal-Singer to its board.

Brandon BioCatalyst portfolio Tue 15 Jun 2021 ENA Respiratory CSIRO GSK Pharmaceuticals International COVID-19 Data Research Alliance Medical Research Commercialisation Fund (MRCF)The University of Sydney University of Melbourne University of Queensland UNSW Sydney US COPD Foundation Brandon Capital Partners Minderoo Foundation Uniseed Dr Andrew Forrest Dr Chris Smith Dr Christophe Demaison Nicola Forrest Ruth Tal-Singer

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·SmartCompany

Something wrong? Tell us